Total pendapatan perusahaan Reata Pharmaceuticals, Inc. (RETA)

Lambang korporat lan logo Reata Pharmaceuticals Inc (RETA)

Reata Pharmaceuticals maintains high margins driven by the Skyclarys patent and the support of a major holding company. The company's current sales volume reflects market dynamics, with the latest value recorded as 0.02. The business relies on the global supply of orphan drugs with low production costs while simultaneously implementing ESG standards to reduce chemical waste and energy consumption in its laboratories.

RETA - Pendapatan perusahaan Reata Pharmaceuticals, Inc. ing rentang 04.07.2022 - 07.10.2023

Rincian analitis perusahaan reatapharma.com (RETA)

- rega saham lan prakiraan rega para ahli:
Analisis komprehensif perusahaan:Reata Pharmaceuticals - RETA
Produk seri Reata Pharmaceuticals

This indicator tracks daily net revenue inflows, allowing investors to identify market trend reversals well before the publication of quarterly reports. By analyzing the sales statistics of Reata Pharmaceuticals (RETA), one can see how the commercial resources of the global biotech behemoth drove rapid revenue growth for its Friedreich's ataxia drug without the need to lower prices to combat competitors.